Roivant Sciences Ltd. – Filings and Transcripts

NASDAQ: ROIV
Share price (8/19/26): $37.40
Market cap (8/19/26): $27.0 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q1

ended 03/31/26 FY 2026

ended 12/31/25 Q3

ended 09/30/25 Q2

ended 06/30/25 Q1

Prospectuses and Registrations Filter

Registration of securities for employees

Automatic shelf registration

Registration of securities for employees

Prospectus supplement for primary offering

Shelf registration

Ownership Filter

Sukhatme Mayukh

Sukhatme Mayukh

Sukhatme Mayukh

Sukhatme Mayukh

Sukhatme Mayukh

News Filter

Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Announces Expansion of Brepocitinib Development Program With New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease

Material Definitive Agreement, Financial Statements or Exhibits

Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Definitive proxy

Additional info about upcoming vote

Additional info about upcoming vote

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Notice of effectiveness

Correspondence with the SEC